Sangamo BioSciences (SGMO) Shares are Up 4.82%

Sangamo BioSciences (SGMO) : Traders are bullish on Sangamo BioSciences (SGMO) as it has outperformed the S&P 500 by a wide margin of 6.25% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 4.26%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 4.82% in the last 1 week, and is up 4.1% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 3.29% and the 50-Day Moving Average is 10.44%.The 200 Day SMA reached 26.87% Sangamo Biosciences Inc. has dropped 18.68% during the last 3-month period . Year-to-Date the stock performance stands at -49.95%.


Sangamo BioSciences (SGMO) : The highest short term price target forecast on Sangamo BioSciences (SGMO) is $30 and the lowest target price is $8. A total of 4 equity analysts are currently covering the company. The average price of all the analysts is $15.25 with a standard deviation of $10.18.

For the current week, the company shares have a recommendation consensus of Buy. Sangamo BioSciences (NASDAQ:SGMO): stock was range-bound between the intraday low of $4.51 and the intraday high of $4.735 after having opened at $4.69 on Fridays session. The stock finally closed in the red at $4.69, a loss of -3.18%. The stock remained in the red for the whole trading day. The total traded volume was 1,382,790 shares. The stock failed to cross $4.735 in Fridays trading. The stocks closing price on Thursday was $4.57.

Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research development and commercialization of engineered DNA-binding proteins as therapeutic products. The main focus for the Company is the development of novel human therapeutics and it is building a pipeline of ZFP Therapeutics. The Companys lead ZFP Therapeutic SB-728-T, a ZFN-modified autologous T-cell product is under development for the treatment of HIV/AIDS. The Companys clinical stage programs also include SB-728-HSPC for the treatment of HIV/AIDS, SB-BCLmR-HSPC to treat Beta-thalassemia major and CERE-110 for the treatment of Alzheimers disease. Its pre-clinical products include SB-913 for the treatment of Hunter Syndrome and SB-318 for the treatment of Hurler Syndrome.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.